Syndax Pharmaceuticals Announces Expected Pricing for IPO

Health and Healthcare

Published: February 22, 2016 11:55 am

Last Updated: January 13, 2020 12:53 pm

Syndax Pharmaceuticals has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company expects to price its 4.4 million shares in the range of $14 to $16, with an overallotment option for an additional 660,000. At the maximum price, the entire offering is valued up to $80.96 million. The company intends to list on the Nasdaq Global Select Market under the symbol SNDX.

The underwriters for this offering are Morgan Stanley, Citigroup, JMP Securities and Oppenheimer.

This clinical stage biopharmaceutical company is developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple negative breast cancer (TNBC). Entinostat is Syndax’s oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. The favorable safety profile of entinostat has been demonstrated in clinical trials in more than 900 cancer patients.

The company is currently evaluating entinostat in combination with Keytruda (pembrolizumab) in a Phase 1b/2 clinical trial for non-small cell lung cancer and melanoma, and it plans to initiate a Phase 1b/2 clinical trial for entinostat in combination with atezolizumab in TNBC in the first half of 2016 and a Phase 1b/2 clinical trial for entinostat in combination with avelumab in ovarian cancer in the second half of 2016. Syndax believes that, based on its mechanism of action, entinostat may have broad applications in additional tumor types, including head and neck, bladder and renal cell, which are immuno-responsive or sensitive to immunotherapy.

Also Syndax is developing entinostat for use in advanced hormone receptor positive (HR+) breast cancer. Following positive results from a Phase 2b clinical trial, ENCORE 301, entinostat in combination with Aromasin (exemestane tablets) was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA), in advanced HR+ breast cancer, for which it is currently being evaluated in a Phase 3 clinical trial.

The company intends to use the net proceeds from this offering to support its clinical trials of entinostat, as well as for working capital and general corporate purposes.

Is Your Money Earning the Best Possible Rate? ^(Sponsor)

Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.

However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.

There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!